For individuals who've plateaued on tirzepatide or semaglutide, by far the most proof-dependent upcoming move in 2026 is optimizing The existing protocol. Altering dose timing, revisiting macronutrient distribution, or incorporating resistance teaching to protect lean mass for the duration of contin